SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Flex Pharma, Inc. (FLKS)

News provided by

Jun 13, 2018, 12:54 ET

NEW YORK, June 13, 2018 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flex Pharma, Inc. ("Flex" or the "Company") (NASDAQ: FLKS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/flks.

The investigation concerns whether Flex and certain of its officers and/or directors have violated federal securities laws.

On June 13, 2018, Flex announced that it plans to halt ongoing Phase 2 clinical trials for FLX-787, the Company's treatment for amyotrophic lateral sclerosis, citing oral tolerability concerns observed in both studies. Flex further announced that the Company will restructure its organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger of the company." On this news, Flex's share price fell sharply during intraday trading on June 13, 2018.

If you are aware of any facts relating to this investigation, or purchased Flex shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/flks. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC